title: Resistance to vancomycin, LY333328, ciprofloxacin and trovafloxacin of community-acquired and nosocomial strains of Enterococcus faecalis isolated in Badajoz (Spain) with and without high-level resistance to streptomycin and gentamicin.
abstract: In vitro resistance of community-acquired and nosocomial strains of Enterococcus faecalis isolated in Badajoz (Spain) were determined by a microdilution method. The isolates were identified with conventional MicroScan Pos Combo 4 I dehydrated panels. No resistance to glycopeptides was found, but LY333328 was 2-4 times more active than vancomycin. In the nosocomial strains, high-level resistance to streptomycin (HLRS) was 54.7%, and high-level resistance to gentamicin (HLRG) was 38.1%. Resistance to ciprofloxacin and trovafloxacin was 45.3 and 38.9%, respectively. In the community-acquired isolates, HLRS, HLRG, resistance to ciprofloxacin and resistance to trovafloxacin were 44.2, 17.3, 15.4 and 13.5%, respectively. Trovafloxacin was 2-4 times more active than ciprofloxacin against both groups of strains. An association between high-level resistance to aminoglycosides and resistance to fluoroquinolones was noted. The resistance to aminoglycosides did not influence the activity of vancomycin and LY333328.
authors.affiliation: Department of Microbiology, Faculty of Medicine, Extremadura University, Avenida de Elvas s/n, 06071 Badajoz, Spain.
authors.forename: R M
authors.initials: RM
authors.lastname: Sánchez-Silos
authors.forename: C
authors.initials: C
authors.lastname: Pérez-Giraldo
authors.forename: M T
authors.initials: MT
authors.lastname: Blanco
authors.forename: F J
authors.initials: FJ
authors.lastname: Morán
authors.forename: C
authors.initials: C
authors.lastname: Hurtado
authors.forename: A C
authors.initials: AC
authors.lastname: Gómez-García
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000890:Anti-Infective Agents / Q000494:pharmacology*; D002939:Ciprofloxacin / Q000494:pharmacology*; D017714:Community-Acquired Infections; D003428:Cross Infection; D024881:Drug Resistance, Bacterial; D013293:Enterococcus faecalis / Q000187:drug effects* / Q000472:pathogenicity; D024841:Fluoroquinolones; D005839:Gentamicins / Q000494:pharmacology*; D006020:Glycopeptides; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy*; D006801:Humans; D015994:Incidence; D000077427:Lipoglycopeptides; D008826:Microbial Sensitivity Tests; D009287:Naphthyridines / Q000494:pharmacology*; D013030:Spain / Q000453:epidemiology; D013307:Streptomycin / Q000494:pharmacology*; D014640:Vancomycin / Q000494:pharmacology* / Q000031:analogs & derivatives
chemical_list: D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D005839:Gentamicins; D006020:Glycopeptides; D000077427:Lipoglycopeptides; D009287:Naphthyridines; D002939:Ciprofloxacin; D014640:Vancomycin; C080163:trovafloxacin; C100708:oritavancin; D013307:Streptomycin